This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors
Hebert, Paul L.,
McBean, Alexander Marshall,
O'Connor, Heidi,
Frank, Barbara,
Good, Charles,
Maciejewski, Matthew L.
Background: Centrally active (CA) angiotensin-converting enzyme inhibitors (ACEIs) are able to cross the blood–brain barrier. Small observational studies and mouse models suggest that use of CA versus non-CA ACEIs is associated with a reduced incidence of Alzheimer’s disease and related dementias (ADRD).; Objective: The aim of this research was to assess the effect of CA […]
Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial
Hajjar, Ihab,
Hart, Meaghan,
Chen, Yu-Ling,
Mack, Wendy,
Novak, Vera,
C. Chui, Helena,
Lipsitz, Lewis
Objectives: To compare the effects of three antihypertensive medications on cerebral hemodynamic and cognitive function in hypertensive individuals with executive dysfunction.; Design: Double-blind randomized clinical trial.; Setting: Community.; Participants: Fifty-three individuals aged 60 and older with hypertension and executive dysfunction.; Intervention: Lisinopril, candesartan, or hydrochlorothiazide for 1 year.; Measurements: Cerebral blood flow velocity (BFV; transcranial […]
Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
Haïk, Stéphane,
Marcon, Gabriella,
Mallet, Alain,
Tettamanti, Mauro,
Welaratne, Arlette,
Giaccone, Giorgio,
Azimi, Shohreh,
Pietrini, Vladimiro,
Fabreguettes, Jean-Roch,
Imperiale, Daniele,
Cesaro, Pierre,
Buffa, Carlo,
Aucan, Christophe,
Lucca, Ugo,
Peckeu, Laurène,
Suardi, Silvia,
Tranchant, Christine,
Zerr, Inga,
Houillier, Caroline,
Redaelli, Veronica,
Vespignani, Hervé,
Campanella, Angela,
Sellal, François,
Krasnianski, Anna,
Seilhean, Danielle,
Heinemann, Uta,
Sedel, Frédéric,
Canovi, Mara,
Gobbi, Marco,
Di Fede, Giuseppe,
Laplanche, Jean-Louis,
Pocchiari, Maurizio,
Salmona, Mario,
Forloni, Gianluigi,
Brandel, Jean-Philippe,
Tagliavini, Fabrizio
Background: Creutzfeldt-Jakob disease (CJD) is a fatal, untreatable prion encephalopathy. Previous studies showed that doxycycline is effective in in-vitro and in-vivo models of disease, and patients with CJD who received compassionate treatment with doxycycline showed increased survival time compared with historical series. We therefore did a randomised, double-blind study of doxycycline versus placebo in CJD.; […]
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease
Geschwind, M. D.,
Kuo, A. L.,
Wong, K. S.,
Haman, A.,
Devereux, G.,
Raudabaugh, B. J.,
Johnson, D. Y.,
Torres-Chae, C. C.,
Finley, R.,
Garcia, P.,
Thai, J. N.,
Cheng, H. Q.,
Neuhaus, J. M.,
Forner, S. A.,
Duncan, J. L.,
Possin, K. L.,
DeArmond, S. J.,
Prusiner, S. B.,
Miller, B. L.
Objective: To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD).; Methods: This NIH/National Institute on Aging-funded, double-blinded, placebo-controlled, stratified randomization treatment trial was conducted at the University of California, San Francisco from February 2005 through May 2009 (ClinicalTrials.gov, NCT00183092). Subjects were randomized (50:50) to quinacrine (300 mg daily) or placebo with inpatient […]